How a Personalised Aesthetic Treatment Plan Is Built, and What to Ask Before You Agree to One

Published 31 March 2026 · Updated 19 August 2026

A treatment plan is the part of aesthetic medicine nobody photographs. It has no before-and-after, it fits on one page, and it decides more about your result than the name of the device does.

This article sets out what the published consensus documents actually say about combining treatments, where the numbers behind the phrase “most patients now prefer a structured approach” come from and who paid for them, and which questions separate a plan from a pre-priced package. Where the evidence runs out, the article says so.

What a treatment plan actually is

A plan names four things: the problem being treated, the order treatments will be done in, the interval between them, and the point at which the plan gets reassessed. Take any of the four away and what remains is a shopping list.

The distinction matters commercially. A package sold at a fixed price for six sessions has decided in advance that you need six sessions, before anyone has seen how you respond to the first. A plan commits to a first step and to a date for looking at the result.

The 2016 consensus published in Dermatologic Surgery puts the sequence in a single sentence: “Optimal aesthetic treatment of the face begins with a thorough patient assessment and an individualized treatment plan.” Assessment first, plan second, devices after that. Most clinic websites, including plenty in Dubai, reverse the order and lead with the machine.

What the Allergan survey found, and who paid for it

In March 2026 Allergan Aesthetics released findings from a consumer study it commissioned, presented at the Aesthetic and Anti-Aging Medicine World Congress in Monaco under the title Layered Beauty: The New Aesthetic Mindset. The headline numbers travelled fast through clinic marketing, usually stripped of their qualifiers. Here they are with the qualifiers attached.

• 62% find multiple aesthetic treatments appealing.
• 59% are likely to adopt a structured multi-treatment approach. This is a stated intention, not a report of what anyone has done, and it is not the same claim as “59% of patients prefer combination treatment”, which is how the figure is usually recycled.
• 78% would feel more satisfied with their aesthetic journey working to an agreed long-term plan with their practitioner.
• 74% intend to improve facial skin quality in the next 12 months, and 63% cite improving elasticity and addressing ageing as top aesthetic goals.
• Around 30% identify skin quality improvement as the starting point for a multi-treatment plan.

The methodology matters as much as the percentages. Allergan surveyed more than 12,286 beauty-involved consumers across nine countries: Canada, the United States, the United Kingdom, China, Brazil, France, Germany, Thailand and Saudi Arabia. Fieldwork ran in November and December 2025. The UAE was not among the nine, so nothing in this dataset describes what patients in Dubai want; the nearest country in the sample is Saudi Arabia.

And the sponsor sells the product category the survey supports. Allergan Aesthetics makes injectables and markets a multimodal treatment framework called AA Signature, which the same press release promotes. A survey funded by a manufacturer, showing consumer appetite for the approach that manufacturer sells, is evidence about consumer attitudes and also a piece of marketing. Both things are true at once. The percentages above are quoted here because they are the only large recent dataset of their kind, not because the source is neutral.

Where the published consensus agrees, and how strongly

Below the survey sits a different kind of document: expert consensus papers, where a panel of specialists votes on statements and the paper reports the percentage who agreed. That is weaker evidence than a randomised trial and stronger than an opinion piece. The honest way to read them is to quote the agreement threshold alongside the recommendation.

Three of them cover combination treatment of the face.

The 2016 pan-facial consensus in Dermatologic Surgery convened fifteen specialists on botulinum toxin, hyaluronic acid, calcium hydroxylapatite and microfocused ultrasound with visualisation, across all Fitzpatrick skin types. Consensus was defined as approval from 75% to 94% of participants; agreement at or above 95% counted as strong consensus. Its own background section notes that at the time of writing, “no guidelines for a pan-facial approach using multiple interventions have been published to date.”

The 2020 guidelines in Clinical, Cosmetic and Investigational Dermatology used a threshold of at least 83% agreement among a multinational board of plastic surgeons and dermatologists. Its conclusion carries a caveat that clinics rarely repeat: “Individual treatment plans should be adapted according to the physician’s individual competence and the patient’s preferences.” Competence of the individual doctor is written into the guideline as a variable. The protocol is not portable between practitioners by itself.

The 2017 Pan-Asian consensus in the Journal of Clinical and Aesthetic Dermatology had eleven specialists and a lower bar, with approval from 70% to 90% counted as moderate consensus. It exists because, in the authors’ words, physicians had been applying guidelines optimised for Caucasian patients to Asian patients for want of anything better. Its finding for combination strategies was largely reassuring: for early intervention, enhancement and restoration, most combination strategies are similar between Asian and Caucasian patients, with beautification a more common focus in the Asian group.

So the recommendations that follow are the collective judgement of between eleven and fifteen doctors per panel, agreed at rates between 70% and 95%. That is useful, and it is not the same thing as a trial.

Most of that evidence is about injectables, and this clinic does not do injectables

Every consensus above was built around botulinum toxin, hyaluronic acid fillers, collagen stimulators and suspension sutures, with energy-based devices in a supporting role. MED YU MED performs none of those. The clinic’s treatment list is device-based and topical: HIFU on Ultraformer MPT, radiofrequency microneedling on Morpheus8, Genius and Vivace, monopolar radiofrequency, Endolift, Fotona laser, INDIBA, LED photodynamic therapy, chemical peels and professional cleansing. No toxin, no filler, no mesotherapy.

That has a consequence for how the guidance above transfers. The principles that are not device-specific carry across: assess before you plan, treat deeper structures before superficial ones, leave enough time between sessions to see what happened, write down when the plan gets reviewed. The specific sequencing rules do not carry across, because a rule about which injectable goes first says nothing about which of two energy devices goes first.

Any clinic quoting the 2016 consensus at you while selling a purely device-based package is quoting a document about a different set of treatments. That includes this one, which is why the limitation is printed here rather than left out.

Sequence, and why order is part of the plan

The clearest sequencing statement in the literature is narrow and worth quoting exactly. From the 2016 consensus: “For same-day treatments, BoNT and fillers may be performed together in either sequence, whereas MFU-V is recommended before injectable agents.”

Unpacked: two injectables on one day can go in either order, but microfocused ultrasound should come before an injectable rather than after it. The reasoning is mechanical. Ultrasound delivers focused thermal energy into tissue, and doing that to an area where a filler has just been placed risks disturbing what you have placed.

The 2022 Asia Pacific paper generalises the same idea into a phrase clinics do use loosely, so here is its actual meaning. The expert panel described an “inside-out” approach, treating the deeper tissue planes before the superficial layers, to achieve harmonious results. Structure first, surface second. A clinic that opens with a resurfacing peel and only afterwards proposes lifting the tissue underneath has the order backwards, and you are entitled to ask why.

Spacing, and where one to two weeks comes from

The interval between sessions is the part of a plan patients most often want compressed, usually because of a wedding, a trip or a holiday. The 2016 consensus gives a figure and, more usefully, a reason: “Spacing consecutive treatments 1 to 2 weeks apart allows for resolution of side effects and/or to assess results.”

Read the second half of that sentence. The gap is not only for swelling and bruising to settle. It is there so that someone can look at what the first treatment did before deciding what the second one should be. Compress the interval and you lose the assessment, which means the second treatment is chosen on assumption rather than on your response.

The one to two week figure belongs to the injectable and ultrasound protocols it was written for. Energy devices that work by controlled thermal injury have their own recovery arcs, and collagen remodelling after radiofrequency microneedling continues for weeks after the visible redness has gone. The transferable principle is the reason, not the number: no second treatment before someone has assessed the first.

Skin quality, and what 153 practitioners across Asia Pacific reported

The 2022 survey in the Journal of Clinical and Aesthetic Dermatology asked medical practitioners in eleven Asia Pacific countries what they were seeing and what they were doing about it. A total of 153 practitioners completed it, and a panel of twelve experts then drafted a practical guide from the results.

The four most common skin quality issues they reported were uneven skin tone, skin surface unevenness, skin laxity, and sebaceous gland hyperactivity with enlarged pores. Two findings from that paper explain why single-treatment thinking breaks down. Most practitioners reported using a combination of treatment modalities for each skin quality issue. And each treatment modality could be used to treat several skin quality issues.

The relationship is many-to-many. There is no clean map from one complaint to one machine, which is precisely why the plan, rather than the device, is the thing worth scrutinising. It also explains why two competent clinics can propose different routes to the same goal without either being wrong.

The paper states its own limit plainly: “Future studies are needed to support the recommended treatment protocols for skin quality improvement.” A practical guide drafted by twelve experts from a survey of 153 colleagues is a reasonable starting framework. It is not proof that the protocols work.

The one place combination therapy has been measured against alternatives

Consensus papers describe what experts advise. For an actual comparison of combinations against single treatments, with numbers, there is one relevant body of work in this field, and it is about acne scarring rather than ageing.

A network meta-analysis published in Archives of Dermatological Research in 2024 pooled 24 randomised controlled trials involving 1,546 participants, comparing microneedling alone against microneedling combined with chemical peels, hyaluronic acid, botulinum toxin-A or platelet-rich plasma, and against platelet-rich plasma, chemical peels or laser therapy on their own. Microneedling combined with chemical peels came out best on degree of improvement, patient satisfaction and treatment efficacy. The authors summarise the general pattern in one line: results for microneedling combined with additional treatments were “obviously better than for MN alone.”

The safety finding is as relevant as the efficacy one. Side effects such as erythema, pain and post-inflammatory hyperpigmentation showed no significant differences across all the treatments assessed. Combining, in this dataset, improved the result without measurably worsening the side effect profile.

Two boundaries on that conclusion. It applies to acne scars in people who have acne scars, not to ageing skin, and not to lifting. And it says nothing about how many sessions or over what timescale. When a clinic cites “the evidence for combination treatment”, this meta-analysis is usually what is being gestured at, and it is narrower than the gesture suggests.

What a first consultation should cover

Assessment before plan is the one point every document above agrees on, so it is fair to judge a consultation by what it examines. A first appointment worth the name records your skin type and phototype, current medications including isotretinoin and anticoagulants, previous aesthetic treatments and when, any history of keloid scarring or cold sores, pregnancy or breastfeeding status, and what specifically bothers you when you look in the mirror.

That last item is not a courtesy. Uneven tone, surface roughness, laxity and enlarged pores are four different problems with four different routes, and patients frequently arrive naming a machine they read about rather than the problem they have.

A consultation that skips the history and moves to pricing is selling. Baseline photographs under fixed lighting are the other marker, because without them nobody can say six months later whether the plan worked, and memory is a generous judge of money already spent.

Questions worth asking before you agree to a package

Six questions, each of which has a right answer that a clinic can give you on the spot.

• What are we treating, in one sentence? If the answer is a device name rather than a problem, the assessment step was skipped.
• Why this order? There should be a reason involving tissue depth or recovery, not the appointment book.
• What is the interval, and what happens in it? The gap exists so someone can assess the first result. Ask who does that and when.
• What would make you change the plan? A plan with no stopping rule is a subscription.
• What is the evidence for this specific combination? “Consensus opinion” is an honest answer. So is “none published for this pairing.” An evasion is not.
• What happens to unused sessions? Worth settling in writing before the first payment, not after the third session.

The 2020 guidelines make one further point that argues against buying a protocol as a commodity: treatment plans should be adapted to the individual physician’s competence. The person performing the treatment is a variable in the outcome, which is a reason to ask who will be holding the device at each session, and not only which device it is.

Risks, and who should not start a combination plan

Combining treatments combines their risks, and the risks are specific to the modality rather than to the plan.

Chemical peels can cause irritation, prolonged redness and changes in pigmentation, and less often scarring. They are not performed on inflamed or infected skin, and not during pregnancy without a doctor’s assessment. Deeper peels on darker skin tones carry a real risk of post-inflammatory hyperpigmentation, which is why phototype belongs in the assessment.

Microneedling and radiofrequency microneedling cause erythema and pain, and post-inflammatory hyperpigmentation is a documented side effect across the trials in the meta-analysis above. Energy-based lifting delivers heat below the skin surface; bruising, swelling and transient numbness are the common complaints, and nerve irritation is the uncommon one.

Some people should not start a plan at all until something else is settled. Active infection or inflammation in the treatment area, current or recent isotretinoin, a history of keloid scarring, pregnancy and breastfeeding, uncontrolled diabetes or a bleeding disorder, and an undiagnosed lesion anywhere in the treatment field all need resolving first. An undiagnosed lesion is the one that matters most, because a treatment plan that resurfaces over it delays a diagnosis.

Nothing here overrides a decision made by the doctor examining you. Suitability is decided at a consultation, not from a web page.

What the evidence does not settle

Four honest gaps, stated because the marketing around this topic tends to imply they are filled.

No randomised trial has compared a structured multi-treatment plan against the same treatments delivered ad hoc, and measured the difference in outcome. The claim that planning improves results is plausible, is endorsed by expert consensus, and is unproven in the sense a trialist would use the word.

The consumer research measures intentions and feelings, not outcomes. Knowing that 78% would feel more satisfied working to an agreed long-term plan tells you about satisfaction, which is worth something and is not the same as knowing their skin ends up in better condition.

Sequencing rules cover injectables in detail and device-only combinations far less. There is no equivalent of the “MFU-V before injectables” rule to tell you whether radiofrequency microneedling should precede or follow a peel in a given case, at a comparable level of evidence.

And session counts are not evidence-based in any published sense. Where a course length comes from a manufacturer’s protocol rather than from a trial, a clinic should be willing to say so.

When this needs a doctor now

Aesthetic planning is elective, and some findings are not. See a doctor promptly if a mole changes in size, shape, colour or border, if a spot bleeds, will not heal within a few weeks, or keeps returning in the same place, or if a patch of skin becomes hot, tender and swollen with fever, which can indicate infection. None of these is a reason for a treatment plan. All of them are a reason for a diagnosis first.

After any procedure, spreading redness with pain and fever, skin that turns white, grey or dusky and stays that way, or sudden vision change needs same-day medical assessment rather than a follow-up appointment. Swelling of the lips, tongue or throat, difficulty breathing or swallowing, or a widespread hive-like rash with faintness means anaphylaxis until proven otherwise. In the UAE, call 998 for an ambulance, and have the person lie down with their legs raised until help arrives.

Medically reviewed by

DR. Alina Lebedeva

General Practitioner, Aesthetic Medicine Doctor, Dermatologist

DHA License No. 35044799-002